Direct contract access to validated analytical methods, clinical-stage trial protocols, and OEM botanical bulk APIs verified under strict pharmaceutical cGMP regulations.
Addressing the paradigm shift from empirical herbal preparations to verifiable, single-molecule precision and chromatographic reproducibility across international regulated markets.
Founded with headquarters in Changsha, Hunan, China, MedGence (Yineng Pharma) operates as a specialized full-chain natural medicine Contract Research Organization (CRO) and Contract Development & Manufacturing Organization (CDMO). We have bridged classical phytotherapy with modern clinical pharmacokinetics, delivering custom programs for more than 100 Class-A tertiary medical institutions and multinational pharmaceutical corporations.
Herbal medicines can only withstand global scrutiny when efficacy claims are fortified by empirical chromatographic fingerprints, validated mechanism-of-action (MoA) profiles, and GLP-certified toxicity documentation. Our laboratories have completed full modernized pharmacodynamics on 83 classic Traditional Chinese Medicine (TCM) formulas, 22 approved innovative natural molecules, and obtained 56 hospital preparation market authorizations.
Under our ISO-certified entrusted research contracts, your molecular entities, formulation ratios, extraction solvent parameters, and clinical master files are guarded under strict non-disclosure legal frameworks. We ensure that all intellectual property generated during contract synthesis, animal pharmacology, and clinical registration belongs exclusively to the corporate client.
Decades of consolidated laboratory metadata across hundreds of thousands of research runs provide our global partners with reduced lead times and predictive regulatory compliance.
Whether commissioning targeted single-assay analytical validations or fully outsourced turnkey CDMO supply, our multidisciplinary teams maintain audit-ready documentation at every tier.
Botanical biomass harbors diverse secondary metabolites including alkaloids, flavonoids, polyphenols, terpenoids, and bioactive polysaccharides. Utilizing multidimensional chromatographic screening and bioactivity-guided fractionation, our analytical teams isolate target bioactive fractions while establishing the most economically viable plant source varieties.
Bioactive concentrations oscillate significantly across varying geographical altitudes, soil micro-ecologies, and climatic harvest windows. We map chromatographic profiles across multiple harvest seasons and genuine (Daodi) regional origins to secure stable raw materials with consistently superior therapeutic potency.
Uncompromising QC demands internationally defensible analytical methodologies. We establish assay protocols via HPTLC (visual authentication), reverse-phase HPLC-DAD/MS (quantitative compound purity), and GC-MS (volatile oil profiling), complete with comprehensive ICH Q2(R1) validation data packages.
Commercial extraction viability hinges on yield kinetics, solvent recyclability, and low-thermal degradation. We engineer optimized parameters across macroporous adsorption resin columns, countercurrent extraction batteries, supercritical CO2 fluids, and membrane concentration units to preserve heat-labile glycosides.
Botanical extracts frequently suffer from hygroscopicity, poor gastrointestinal permeability, and astringent organoleptic profiles. Our pharmaceutical formulation scientists resolve phase separation, oxidative degradation, and low dissolution rates through microencapsulation, cyclodextrin complexation, and solid dispersion techniques.
Eliminate downstream regulatory barriers with comprehensive preclinical toxicity suites. Our laboratories conduct acute oral LD50 determination, 28-day and 90-day sub-chronic repeated dose studies, bacterial reverse mutation (Ames assay), in vitro mammalian chromosomal aberration, and in vivo micronucleus tests.
Elucidate biological activity at cellular and receptor levels prior to live-animal interventions. We run automated enzyme inhibition profiles (COX-2, 5-LOX, α-glucosidase), free radical neutralizing capacity (ORAC, DPPH), macrophage anti-inflammatory response pathways, and oncological antiproliferative screenings.
Validate clinical hypotheses using established murine, rat, and rabbit disease models. Specializations include diet-induced metabolic disorders, streptozotocin diabetic models, osteoarthritis cartilage degradation models, cognitive impairment scenarios, and mucosal tissue regenerative evaluation.
From randomized double-blind placebo-controlled human trials for high-tier dietary supplement functional claim substantiation to rigorous multi-center Phase I, II, III, and IV studies for pharmaceutical botanical new drug applications (NDAs), we handle full GCP trial management.
Leveraging 83 completed classic TCM formula clinical research dossiers, our teams dissect multi-herb decoctions to decode synergistic botanical interactions. We systematically eliminate toxic constituents while retaining therapeutic holistic polypharmacology for global nutraceutical registration.
Operate seamlessly from our centralized pilot plant to high-capacity collaborative manufacturing facilities. We supply bulk active ingredients in various high-purity physical forms: micro-pulverized powders, standardized fluid extracts, solvent-free oleoresins, vacuum-dried pastes, and aromatic volatile essential oils.
Complete commercial contract packaging compliant with global pharmaceutical criteria. Capabilities cover oral liquids, vegetarian capsules, enteric-coated softgels, bi-layer sustained-release tablets, effervescent granules, and moisture-barrier stick pouches with automated tamper-evident serialization.
Why Tier-1 international brand owners concentrate their raw material sourcing and extraction partnerships within China's specialized chemical and botanical manufacturing clusters.
China commands over 12,000 recorded medicinal plant species across diverse climatic terrains—from the sub-alpine plateaus of Yunnan and Sichuan to the temperate deciduous zones of Jilin and Heilongjiang. MedGence maintains direct strategic partnerships with certified Good Agricultural Practices (GAP) cultivation bases. This direct agricultural architecture mitigates wildcrafting depletion, guarantees non-GMO botanical authenticity, and locks in competitive feedstock prices regardless of global trade volatility.
The concentration of specialty chemical fabricators, solvent recycling infrastructure, and high-tonnage stainless steel pressure vessel manufacturers in China provides unrivaled CDMO engineering speed. Our Hunan production bases leverage continuous countercurrent extraction lines processing 10,000 metric tons of raw herb annually, coupled with solvent-free closed-loop recycling that lowers industrial energy consumption while delivering pure extracts free from toxic petro-solvent impurities.
A rigorous quality control architecture engineered specifically to navigate the increasingly harmonized pharmacopeial monographs and contaminant thresholds mandated by international regulatory agencies.
| Critical Quality Attribute (CQA) | United States (FDA / USP) | European Union (EMA / Ph. Eur.) | MedGence Internal Release Standard |
|---|---|---|---|
| Heavy Metals (ICP-MS) | USP <232>/<233>: Pb ≤ 0.5 ppm, Cd ≤ 0.5 ppm, As ≤ 1.5 ppm, Hg ≤ 0.1 ppm | Ph. Eur. 2.4.27: Pb ≤ 3.0 ppm, Cd ≤ 1.0 ppm, Hg ≤ 0.1 ppm | Pharma Grade: Total Heavy Metals < 5 ppm; Pb < 0.2 ppm, Cd < 0.1 ppm |
| Pesticide Residues (LC-MS/MS) | USP <561> multi-residue screen (70+ targeted organophosphates) | Ph. Eur. 2.8.13 multi-residue compliance (>200 target compounds) | Dual-platform GC-MS/MS & LC-MS/MS verification; 100% Non-detectable limit |
| Residual Solvents (GC-FID) | USP <467> Class 1 (prohibited), Class 2 (strict limits), Class 3 (<5000 ppm) | Ph. Eur. 5.4 / ICH Q3C Harmonized Guidelines | Ethanol/Water processing only; total VOC residues validated < 500 ppm |
| Microbiological Limits | USP <2021>/<2022> TAMC <10³ CFU/g; Absence of Salmonella & E. coli | Ph. Eur. 5.1.8 Category A/B standards for oral phytomedicines | TAMC <100 CFU/g; TYMC <10 CFU/g; Total pathogen negative; Irradiation-free |
| Aflatoxins & Mycotoxins | Total Aflatoxins (B1+B2+G1+G2) < 20 ppb; Aflatoxin B1 < 5 ppb | Ph. Eur. 2.8.18: Aflatoxin B1 ≤ 2 µg/kg; Total aflatoxins ≤ 4 µg/kg | Immunoaffinity purification; HPLC-FLD validation; B1 < 1 µg/kg |
A strategic evaluation framework for enterprise supply chain executives and corporate R&D directors navigating botanical API procurement.
Limitations: Lack internal chromatographic laboratories. Re-sell variable market batches with erratic active compound contents. Certificates of Analysis (COAs) are frequently copied or untested for adulterants like synthetic dyes or undeclared pharmaceutical enhancers.
Limitations: Capable of bulk solvent processing but completely disconnected from clinical trial protocol designs, pharmacology, or formulation stability. Unable to troubleshoot sudden batch crystallization, moisture migration, or regional regulatory inquiries.
Total Synergy: In-house phytochemists manage raw sourcing through to finished retail blister packs. Batch-to-batch stability guaranteed by chromatographic fingerprinting. Complete regulatory DMF (Drug Master File) support for FDA and EMA filings.
Investment into next-generation extraction modalities, green engineering, and artificial intelligence to elevate botanical product efficacy and purity.
By marrying machine learning predictive algorithms with our extensive library of plant secondary metabolites, we predict ligand-protein binding affinities against human therapeutic targets, reducing preclinical drug discovery timelines from years to months.
Moving beyond conventional hydrocarbon solvents, we deploy enzyme-assisted lysis to breakdown robust plant cell walls, paired with pressurized subcritical water extraction at precise dielectric constants to isolate pure polyphenol fractions without synthetic chemical residues.
Maximizing pharmacokinetic bioavailability through pharmaceutical-grade self-emulsifying drug delivery systems (SEDDS) and phospholipid nanoliposomes, preventing gastrointestinal enzyme destruction of sensitive botanical glycosides.
Engineered to align directly with commercial packaging configurations, regulatory label claims, and product delivery matrices.
High-potency standardized botanical extracts with certified biomarker percentages (e.g., Ginsenosides, Berberine, Curcuminoids) formulated for high-speed tableting, two-piece hard gelatin or pullulan capsules, and liquid-filled vegetarian softgels.
Drug Master File (DMF) backed botanical APIs developed in alignment with FDA Botanical Drug Development Guidance and EMA Committee on Herbal Medicinal Products (HMPC) clinical protocols.
Ultra-pure, decolorized, and hypoallergenic botanical actives tailored for topical skin barrier repair, transdermal anti-aging serums, scalp microbiota revitalization, and photoprotective clinical skin regimens.
Our long-term scientific and manufacturing programs support China's top-tier national pharmaceutical manufacturers, listed enterprises, and university clinical research hospitals.
Beijing Tongrentang Group
CR Sanjiu Medical & Pharma
Sunflower Pharmaceutical
Livzon Pharmaceutical Group
Dihon Pharmaceutical
Golden Throat Holdings
Yangtzi River Pharmaceutical
Beihai Gofar Biological
Humanwell Healthcare Group
SCIMYTH Pharmaceutical
Shandong Hanfang Pharma
Luoxin Pharmaceutical Group
Guangdong Zhongsheng
Hunan Brilliance Herbal
Apeloa Pharmaceutical
Hunan Heng Chang Pharma
Baotou TCM Co.
Kamp Medicine Co.
Guangxi Santo Pharma
Hunan Kangshou Pharma
Jiangxi Juwang Pharma
Beijing Tcmages Pharma
Guizhou Ruihe Pharma
Anhui CR Jinchan Pharma
Kangmei Pharmaceutical
Tianjicaotang Pharma
Kingstone Unite Pharma
Shuguang Hospital (Shanghai)
Hunan Directly Affiliated TCM Hospital
First Hospital of Hunan Univ TCM
Second Xiangya Hospital
Second Hospital of Hunan TCM
Orthopedics of TCM ZhuzhouComprehensive answers addressing technology transfer, international regulatory dossiers, quality testing, and supply chain accountability.
Direct supply contracts, technical evaluations, and custom pilot batches available immediately for international B2B buyers and pharmaceutical formulators.
Connect directly with our Changsha scientific committee to scope custom phytochemical extraction protocols, analytical method validations, in vivo pharmacology, or cGMP commercial manufacturing schedules.
